Acerus Pharmaceuticals Co. (TSE:ASP) Director Stephen Robert Gregory purchased 320,000 shares of the firm’s stock in a transaction that occurred on Friday, December 7th. The stock was purchased at an average price of C$0.14 per share, for a total transaction of C$44,800.00.
Stephen Robert Gregory also recently made the following trade(s):
- On Monday, September 10th, Stephen Robert Gregory purchased 94,000 shares of Acerus Pharmaceuticals stock. The stock was purchased at an average price of C$0.24 per share, for a total transaction of C$22,560.00.
Acerus Pharmaceuticals stock traded up C$0.01 during mid-day trading on Friday, hitting C$0.14. The stock had a trading volume of 358,600 shares, compared to its average volume of 201,706. Acerus Pharmaceuticals Co. has a 12 month low of C$0.12 and a 12 month high of C$0.42. The company has a current ratio of 0.69, a quick ratio of 0.29 and a debt-to-equity ratio of 105.08.
TRADEMARK VIOLATION WARNING: This report was published by Equities Focus and is the property of of Equities Focus. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.equitiesfocus.com/2018/12/08/insider-buying-acerus-pharmaceuticals-co-asp-director-acquires-320000-shares-of-stock.html.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.
Recommended Story: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.